Folic acid, Vitamin B12, MTHFR genotypes and plasma homocysteine
Golledge, Jonathan, Jones, Leonie, Oliver, Lisa, Quigley, Francis, and Karan, Mirko (2006) Folic acid, Vitamin B12, MTHFR genotypes and plasma homocysteine. Clinical Chemistry , 52 (6). pp. 1205-1206.
PDF (Published Version)
- Published Version
Restricted to Repository staff only
[Extract] We read with interest the article by Pastore et al. (1), who demonstrated that the effect of folate and vitamin B12 treatment in reducing total plasma homocysteine (tHcy) concentration is dependent on methylenetetrahydrofolate reductase (MTHFR) genotype in patients with end-stage renal failure. Their findings may partially explain the difficulty in demonstrating a benefit of vitamin supplementation in reducing cardiovascular end-point, as treatment may have to be tailored to subgroups of patients such as those with the MTHFR T allele (2)(3). Although tHcy concentrations are much lower in individuals with normal renal function, they still predict subsequent cardiovascular events (4).
|Item Type:||Article (Editorial)|
|Keywords:||homocysteine; folic acid; Vitamin B12; MTHFR genotypes; cardiovascular diseases|
|Date Deposited:||27 Nov 2009 02:51|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110201 Cardiology (incl Cardiovascular Diseases) @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100%|
|Citation Count from Web of Science||